RecruitingNot ApplicableNCT07607353

Biodegradable Stents in Primary Sclerosing Cholangitis

Pilot Study of Biodegradable STents in Primary Sclerosing Cholangitis - BSTPSC


Sponsor

King's College Hospital NHS Trust

Enrollment

20 participants

Start Date

Mar 1, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

In patients with PSC, endoscopic therapy of strictures aims to improve cholestasis by relieving the biliary obstruction via endoscopic biliary dilatation with consideration of plastic stents in strictures refractory to dilatation due to the risk of pancreatitis and cholangitis . Short term stents have been shown to have similar recurrence-free rates compared to dilatation in a randomised control trial; however, this was terminated after interim analysis due to higher rates of serious adverse events in the stent group. The long term benefits are unclear; however, it may lead to improved survival compared to predicted survival. In this group of patients with limited treatment options, biodegradable stents may provide an attractive additional treatment modality in the management of high grade strictures.


Eligibility

Min Age: 18 Years

Inclusion Criteria1

  • PSC patients with a high grade stricture

Exclusion Criteria11

  • Prior stenting or balloon dilatation within the previous 4 months
  • Signs of bacterial cholangitis as defined by definite cholangitis
  • Change of UDCA therapy within 4 weeks
  • Inability to give informed consent
  • Biliary cirrhosis with Child Pugh score > 8
  • Estimated transplant free survival < 2 years as calculated by Mayo score > 2
  • Suspicion of cholangiocarcinoma, reflected by an imaging study suggestive of metastasis, MRCP with mass lesion with contrast enhancenment, or rise in CA19.9 of > 63 U/ml in the previous 4 months together with an absolute value > 130 U/ml
  • Signs of current malignancy other than basal cell carcinoma
  • Life expectancy < 24 months
  • Women pregnant at the time of screening
  • HIV or acute or chronic hepatitis B or hepatitis C or substance (drug or alcohol) misure within the previous 2 years.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEarchimedes stent

archimedes stent for HGS


Locations(1)

King's College Hospital, London

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07607353


Related Trials